On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

Alnylam Pharmaceuticals Inc (NASDAQ ... driven by a gross to net adjustment in Portugal and large orders in partner markets in Q2. Net revenue from collaborations decreased by $370 million ...

Good day, everyone, and welcome to today's Alnylam Pharmaceuticals Q3 2024 Earnings ... decrease was driven by a gross to net adjustment in Portugal that was booked in Q3 and large orders of ...

and Portugal. In addition, he is the managing director of Alnylam Netherlands. Murthy is also the head of market access, pricing, and public policy, overseeing the company’s interactions with ...

--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran ...

Alnylam Pharmaceuticals' product revenues grew at a healthy pace, but on other fronts, it struggled. Alnylam Pharmaceuticals is a biotechnology firm specializing in RNAi therapies, which can ...

Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals ALNY revealed 11 unusual trades. Delving into the ...

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $400.00. Don't Miss our Black Friday ...

Alnylam Pharmaceuticals ALNY reported third-quarter 2024 adjusted loss of 50 cents per share, which matched the Zacks Consensus Estimate. The company had recorded earnings of $1.74 per share in ...

But the incumbents look set to fight to hold onto the market, with Alnylam Pharmaceuticals sharing early-phase data on its next-generation prospect. Alnylam currently competes with Pfizer for the ...